Treatment of Hormone Refractory Immune Thrombocytopenia

［Abstract］Objective　To explore the treatment of hormone refractory immune thrombocytopenia．Methods　A retrospective analysis was performed on clinical data of 75 cases of patients with ineffective hormone therapy in our hospital from February 2013 to February 2015， and the patients were divided into control group （37 cases） and observation group（38 cases）according to treatment methods，and were given treatment of vincristine treatment and recombinant human thrombopoietin，respectively. Clinical effect of the two groups were observed and compared. Results After different treatment，the curative effect，the total efficiency of observation group was 84.21%， significantly higher than 64.86% in the control group，the difference was statistically significant（P < 0.05），before treatment， no significant difference was found in the platelet counts of the 2 groups of patients， the difference was not statistically significant（P > 0.05）. Compared with before treatment，on 7d， 14d， 21d after different treatment， the levels of platelet count of patients in 2 groups were significantly increased. And the levels of platelet count of patients in the observation group were significantly higher than those in the control group on 7d，14d，21d after different treatment（P < 0.05）. The incidence of adverse reactions in the observation group was significantly lower than that in the control group（P < 0.05）. Conclusion For hormone refractory immune thrombocytopenic patients， recombinant human thrombopoietin treatment has better clinical efficacy than vincristine treatment.